268 related articles for article (PubMed ID: 15285777)
1. Levodopa effect on [18F]fluorodopa influx to brain: normal volunteers and patients with Parkinson's disease.
Kumakura Y; Danielsen EH; Reilhac A; Gjedde A; Cumming P
Acta Neurol Scand; 2004 Sep; 110(3):188-95. PubMed ID: 15285777
[TBL] [Abstract][Full Text] [Related]
2. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms.
Kumakura Y; Gjedde A; Danielsen EH; Christensen S; Cumming P
J Cereb Blood Flow Metab; 2006 Mar; 26(3):358-70. PubMed ID: 16079784
[TBL] [Abstract][Full Text] [Related]
3. Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects.
Rousset OG; Deep P; Kuwabara H; Evans AC; Gjedde AH; Cumming P
Synapse; 2000 Aug; 37(2):81-9. PubMed ID: 10881028
[TBL] [Abstract][Full Text] [Related]
4. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
[TBL] [Abstract][Full Text] [Related]
5. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
[TBL] [Abstract][Full Text] [Related]
6. 6-[18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods.
Hoshi H; Kuwabara H; Léger G; Cumming P; Guttman M; Gjedde A
J Cereb Blood Flow Metab; 1993 Jan; 13(1):57-69. PubMed ID: 8417011
[TBL] [Abstract][Full Text] [Related]
7. Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge.
Vernaleken I; Kumakura Y; Cumming P; Buchholz HG; Siessmeier T; Stoeter P; Müller MJ; Bartenstein P; Gründer G
Neuroimage; 2006 May; 30(4):1332-9. PubMed ID: 16439159
[TBL] [Abstract][Full Text] [Related]
8. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data.
Sawle GV; Playford ED; Burn DJ; Cunningham VJ; Brooks DJ
Arch Neurol; 1994 Mar; 51(3):237-43. PubMed ID: 8129633
[TBL] [Abstract][Full Text] [Related]
9. PET studies on brain monoamine transporters with carbon-11-beta-CIT in Parkinson's disease.
Laihinen AO; Rinne JO; Någren KA; Lehikoinen PK; Oikonen VJ; Ruotsalainen UH; Ruottinen HM; Rinne UK
J Nucl Med; 1995 Jul; 36(7):1263-7. PubMed ID: 7790953
[TBL] [Abstract][Full Text] [Related]
10. PET studies of net blood-brain clearance of FDOPA to human brain: age-dependent decline of [18F]fluorodopamine storage capacity.
Kumakura Y; Vernaleken I; Gründer G; Bartenstein P; Gjedde A; Cumming P
J Cereb Blood Flow Metab; 2005 Jul; 25(7):807-19. PubMed ID: 15729292
[TBL] [Abstract][Full Text] [Related]
11. 'Prefrontal' cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: an exploratory [18F]-fluoro-L-DOPA-PET investigation.
Vernaleken I; Buchholz HG; Kumakura Y; Siessmeier T; Stoeter P; Bartenstein P; Cumming P; Gründer G
Hum Brain Mapp; 2007 Oct; 28(10):931-9. PubMed ID: 17133402
[TBL] [Abstract][Full Text] [Related]
12. PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches.
Kumakura Y; Cumming P
Neuroscientist; 2009 Dec; 15(6):635-50. PubMed ID: 19793723
[TBL] [Abstract][Full Text] [Related]
13. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease.
Ceravolo R; Piccini P; Bailey DL; Jorga KM; Bryson H; Brooks DJ
Synapse; 2002 Mar; 43(3):201-7. PubMed ID: 11793426
[TBL] [Abstract][Full Text] [Related]
14. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.
Leenders KL; Salmon EP; Tyrrell P; Perani D; Brooks DJ; Sager H; Jones T; Marsden CD; Frackowiak RS
Arch Neurol; 1990 Dec; 47(12):1290-8. PubMed ID: 2123623
[TBL] [Abstract][Full Text] [Related]
15. Monosymptomatic resting tremor and Parkinson's disease: a multitracer positron emission tomographic study.
Ghaemi M; Raethjen J; Hilker R; Rudolf J; Sobesky J; Deuschl G; Heiss WD
Mov Disord; 2002 Jul; 17(4):782-8. PubMed ID: 12210876
[TBL] [Abstract][Full Text] [Related]
16. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.
Sawle GV; Burn DJ; Morrish PK; Lammertsma AA; Snow BJ; Luthra S; Osman S; Brooks DJ
Neurology; 1994 Jul; 44(7):1292-7. PubMed ID: 8035933
[TBL] [Abstract][Full Text] [Related]
17. Brain 6-[18F]fluorodopa metabolism in early and late onset of Parkinson's disease studied by positron emission tomography.
Nagasawa H; Tanji H; Itoyama Y; Saito H; Kimura I; Fujiwara T; Iwata R; Itoh M; Ido T
J Neurol Sci; 1996 Dec; 144(1-2):70-6. PubMed ID: 8994106
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease.
Torstenson R; Hartvig P; Långström B; Westerberg G; Tedroff J
Ann Neurol; 1997 Mar; 41(3):334-40. PubMed ID: 9066354
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography in Parkinson's disease: glucose and DOPA metabolism.
Martin WR; Stoessl AJ; Adam MJ; Ammann W; Bergstrom M; Harrop R; Laihinen A; Rogers JG; Ruth TJ; Sayre CI
Adv Neurol; 1987; 45():95-8. PubMed ID: 3103398
[No Abstract] [Full Text] [Related]
20. Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants.
Sawle GV; Bloomfield PM; Björklund A; Brooks DJ; Brundin P; Leenders KL; Lindvall O; Marsden CD; Rehncrona S; Widner H
Ann Neurol; 1992 Feb; 31(2):166-73. PubMed ID: 1575455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
